OptiMedica Inc., a Santa Clara, Calif.-based ophthalmic device company, has raised $16 million in Series C funding. DAG Ventures was joined by return backers Kleiner Perkins Caufield & Byers and Alloy Ventures.
OptiMedica Corp., a global ophthalmic device company, has announced the receipt of $16 million in Series C financing. Participants in the round included the company's existing venture investors, Kleiner, Perkins, Caufield & Byers and Alloy Ventures, as well as new investment partner DAG Ventures. The Series C financing will be used towards the expansion of OptiMedica's commercial presence and the development of its new technology portfolio.
“Our further support of OptiMedica represents our strong, continued belief in the significant advances the company is contributing to the field of ophthalmology for the benefit of patients across the globe,” said Brook Byers, partner, Kleiner, Perkins, Caufield & Byers, and chairman of the board, OptiMedica. “We are very optimistic about the company's immediate growth prospects and long-term technology pipeline.”
Founded in 2004, OptiMedica has the exclusive worldwide rights to and has commercialized the groundbreaking PASCAL(